Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 349

Results For "Development"

3672 News Found

Max Healthcare to set up a 500-bed capacity hospital in Delhi
Healthcare | August 28, 2021

Max Healthcare to set up a 500-bed capacity hospital in Delhi

This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024


Covid-19 infected individuals need only one dose of Covaxin: ICMR study
News | August 28, 2021

Covid-19 infected individuals need only one dose of Covaxin: ICMR study

Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021


Roche withdraws the US accelerated approval for Tecentriq
Drug Approval | August 28, 2021

Roche withdraws the US accelerated approval for Tecentriq

Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider


Brazil’s Eurofarma to manufacture Comirnaty for Latin America
Biotech | August 27, 2021

Brazil’s Eurofarma to manufacture Comirnaty for Latin America

The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually


Merck donates Rs 1.7 crore to IIT Bombay for Covid-19 research
News | August 26, 2021

Merck donates Rs 1.7 crore to IIT Bombay for Covid-19 research

The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology


RedHill Biopharma's Opaganib demonstrates strong inhibition of COVID-19 Delta variant
Drug Approval | August 26, 2021

RedHill Biopharma's Opaganib demonstrates strong inhibition of COVID-19 Delta variant

Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease


Johnson & Johnson booster dose indicate impressive results
Drug Approval | August 26, 2021

Johnson & Johnson booster dose indicate impressive results

New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.


Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin
Drug Approval | August 26, 2021

Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin

The company to receive upfront and milestone payments, in addition to royalties


Sai Life Sciences is now a United Nations Global Compact (UNGC) signatory
News | August 26, 2021

Sai Life Sciences is now a United Nations Global Compact (UNGC) signatory

In the last two years, Sai Life Sciences has made significant investments and progress in advancing its sustainability agenda as part of its organizational transformation initiative


Encision signs supply agreement with Auris Health
Healthcare | August 25, 2021

Encision signs supply agreement with Auris Health

The company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures